晚期肺腺癌组织中TYMS基因表达水平判定及其临床意义验证

Abstract
Figure/Table
References
Related Citation (8)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To examine the relative expression of TYMS gene in 150 FFPE samples of advanced lung adenocarcinoma patients and to validate the method for differentiating TYMS gene expression levels in term of clinical significance. Methods Real time quantitative PCR and 2^-△Ct method was used to detect the expression of TYMS and internal reference gene. The median value was used as the cut-off value and retrospective validation was performed including the short and long term therapeutic response towards pemetrexed based chemotherapy. Results In the 150 samples we examined, the detection rate was 89.3% when both the TYMS and the internal reference gene were successfully amplified. TYMS expression was significantly correlated with late stage adenocarcinoma patients’ age groups (P=0.025) but not significantly correlated with patients’ gender, histology, stage or smoking history (P＞0.05). The ORR (Objective response rate) in TYMS high and low expression groups was 9.8% and 35.4%, respectively (P<0.05). The median progression free survival time in TYMS high and low expression group was 2.1 and 4.9 months, respectively (P=0.047). The median overall survival time in TYMS high and low expression group was 9.1 and 16.7 months, respectively (P=0.024). Conclusions The method for differentiating TYMS gene expression levels in the present study is suitable in late stage adenocarcinoma patients and sheds light on the standardization of TYMS expression detection. This method can also be used to predict the therapeutic efficiency of pemetrexed chemotherapy.

Key words： lung adenocarcinoma TYMS expression cut-off value

Received: 17 April 2014

ZTFLH:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Zhihao
	ZHU Youcai
	WU Dongqiang
	XIAO Huaiqing
	GUO Dawei
	WANG Xiyong
	CHEN Huafei
	LI Xiaofeng
	DU Kaiqi

Cite this article:

ZHANG Zhihao,ZHU Youcai,WU Dongqiang等. Evaluation of TYMS gene expression level and its clinical significance in advanced lung adenocarcinoma[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(1): 19-22.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2015/V26/I1/19

[1]	Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA: A Cancer Journal for Clinicians, 2011, 61(2): 69-90.
[1]	Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA: A Cancer Journal for Clinicians, 2011, 61(2): 69-90.
[2]	Muhsin M, Gricks C, Kirkpatrick P. Pemetrexed disodium[J]. Nat Rev Drug Discov, 2004, 3(10): 825-826.
[2]	Muhsin M, Gricks C, Kirkpatrick P. Pemetrexed disodium[J]. Nat Rev Drug Discov, 2004, 3(10): 825-826.
[3]	李兰芳, 胡歌, 刘贤, 等.吉西他滨联合培美曲塞治疗晚期非小细胞肺癌[J]. 实用肿瘤杂志, 2010, (5): 578-580.
[3]	李兰芳, 胡歌, 刘贤, 等.吉西他滨联合培美曲塞治疗晚期非小细胞肺癌[J]. 实用肿瘤杂志, 2010, (5): 578-580.
[4]	张雪艳, 黄艾弥, 白皓, 等.培美曲塞单药或联合化疗治疗晚期复发性非小细胞肺癌68例分析[J]. 中国癌症杂志, 2009, 26(2): 118-121.
[4]	张雪艳, 黄艾弥, 白皓, 等.培美曲塞单药或联合化疗治疗晚期复发性非小细胞肺癌68例分析[J]. 中国癌症杂志, 2009, 26(2): 118-121.
[5]	Rouquette I, Mazieres J. A brief overview of a lung cancer biomarker: thymidylate synthase[J]. Revue des maladies respiratoires, 2011, 28(6):773-777.
[5]	Rouquette I, Mazieres J. A brief overview of a lung cancer biomarker: thymidylate synthase[J]. Revue des maladies respiratoires, 2011, 28(6):773-777.
[6]	李艳, 章明放, 郭雪西, 等. 胃腺癌中P-gp、ToPoⅡ、GSTπ、MGMT和TS的表达及意义[J]. 临床与实验病理学杂志, 2011, 23(11):45-48.
[6]	李艳, 章明放, 郭雪西, 等. 胃腺癌中P-gp、ToPoⅡ、GSTπ、MGMT和TS的表达及意义[J]. 临床与实验病理学杂志, 2011, 23(11):45-48.
[7]	郑巧荣, 崔金全. 宫颈上皮内瘤变及宫颈癌中TS、PCNA的表达及其意义[J]. 中国妇幼保健, 2011, 21(7):125-127.
[7]	郑巧荣, 崔金全. 宫颈上皮内瘤变及宫颈癌中TS、PCNA的表达及其意义[J]. 中国妇幼保健, 2011, 21(7):125-127.
[8]	黄慧敏, 李惠翔, 张红, 等. RNAi对人乳腺癌MCF-7细胞E2F1、TS基因表达的抑制作用[J]. 山东医药, 2008, 43(1):14-15.
[9]	李世拥, 于波, 安萍, 等.胸苷酸合成酶基因表达与结肠直肠癌复发的关系及其临床意义[J]. 中华外科杂志, 2000, 52(10):60-62.
[8]	黄慧敏, 李惠翔, 张红, 等. RNAi对人乳腺癌MCF-7细胞E2F1、TS基因表达的抑制作用[J]. 山东医药, 2008, 43(1):14-15.
[10]	Ozasa H, Oguri T, Uemura T, et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer[J]. Cancer science, 2010, 101(1):161-166.
[9]	李世拥, 于波, 安萍, 等.胸苷酸合成酶基因表达与结肠直肠癌复发的关系及其临床意义[J]. 中华外科杂志, 2000, 52(10):60-62.
[10]	Ozasa H, Oguri T, Uemura T, et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer[J]. Cancer science, 2010, 101(1):161-166.
[11]	Roe O D, Szulkin A, Anderssen E, et al. Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma[J]. PloS one, 2012, 7(8): e40521.
[11]	Roe O D, Szulkin A, Anderssen E, et al. Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma[J]. PloS one, 2012, 7(8): e40521.
[12]	Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer[J]. British J cancer, 2011, 104(10): 1594-1601.
[12]	Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer[J]. British J cancer, 2011, 104(10): 1594-1601.
[13]	Mairinger F, Vollbrecht C, Halbwedl I, et al. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma[J]. J Thorac Oncol, 2013, 8(5): 644-653
[14]	Zucali P A, Giovannetti E, Destro A, et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin[J]. Clinical Cancer Research, 2011, 17(8): 2581-2590.
[13]	Mairinger F, Vollbrecht C, Halbwedl I, et al. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma[J]. J Thorac Oncol, 2013, 8(5): 644-653
[14]	Zucali P A, Giovannetti E, Destro A, et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin[J]. Clinical Cancer Research, 2011, 17(8): 2581-2590.
[15]	Bepler G, Sommers K E, Cantor A, et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer[J]. J Thorac Oncol, 2008, 3(10):1112-1118.
[15]	Bepler G, Sommers K E, Cantor A, et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer[J]. J Thorac Oncol, 2008, 3(10):1112-1118.
[16]	Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy[J]. J Clini Oncol, 2001, 19(23):4298-4304.
[16]	Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy[J]. J Clini Oncol, 2001, 19(23):4298-4304.